PROTAC PEG

PROTAC PEG

The design of Proteolysis Targeting Chimera (PROTACs) is a powerful small molecule approach for inducing protein degradation for anticancer therapy. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. To further empower the PROTAC study, BroadPharm are developing a series of PROTAC  linker to accelerate our customers’  R&D effort.
Product Number
Product Name
Structure
M.W.
Purity
4-Hydroxy-thalidomide
274.2
98%
 
 
Thalidomide-Acid
332.3
98%
 
 
Thalidomide-O-PEG4-Amine
493.5
98%
 
 
Thalidomide-O-PEG4-Azide
519.5
98%
 
Thalidomide-O-amido-PEG4-azide
576.6
98%
 
 
Thalidomide-O-PEG4-NHS ester
619.6
98%
 
 
Thalidomide-O-PEG4-Propargyl
488.5
98%
 
Thalidomide-O-amido-PEG4-propargyl
546.5
98%
 
 
Thalidomide-O-PEG4-t-butyl ester
578.6
98%
 
 
Thalidomide-O-PEG5-Tosyl
648.6
98%
 
 
4-Fluoro-thalidomide
276.2
98%
 
 
Pomalidomide
273.2
98%
 
 
Pomalidomide-PEG4--Azide
518.5
98%
 
Pomalidomide-PEG5-Azide
590.6
98%
 
 
D-Biotin-PEG6-Thalidomide
791.9
98%
 
 
D-Amino-PEG6-Thalidomide TFA salt
565.6
98%
 
 
VHL Ligand 1 HCl salt
430.6
98%
 
 
(S,R. S)-AHPC-pentanoic-acid
558.7
98%
(S,R. S)-AHPC-PEG2-acid
618.8
98%
(S,R. S)-AHPC-PEG3-acid
662.8
98%
(S,R.S)-AHPC-PEG4-acid
706.9
98%
(S,R. S)-AHPC-PEG8-acid
883.0
98%
 
 
(S,R. S)-AHPC-PEG2-amine hydrochloride salt
575.7
98%
(S,R. S)-AHPC-PEG4-amine hydrochloride salt
663.8
98%
 
 
(S,R. S)-AHPC-PEG4-Azide
703.9
98%
 
 
(S,R. S)-AHPC-PEG4-tosyl
789.0
97%